• Singapore Expansion Supports Growing Healthcare and Pharma Markets
    L-R: Bernard Birkett, Senior Vice President, Chief Financial and Operations Officer; Marcus Tang, Senior Director, Operations, Jurong; Eric Green, President, CEO and Chair of the Board of Directors; Goh Wan Yee, SVP and Head of Healthcare, EDB; and Alagu Subramaniam, Senior Director, Sales and Commercial Operations, Asia Pacific at the inauguration ceremony of West's upgraded manufacturing facility in Singapore

News & Views

Singapore Expansion Supports Growing Healthcare and Pharma Markets

Jul 11 2023

West Pharmaceutical Services, Inc, a global leader in innovative solutions for injectable drug administration, has officially opened its state-of-the-art manufacturing facility in Jurong, Singapore. This investment is part of West's commitment to a global investment of over US$350 million in 2023, primarily focused on expanding capacity and meeting the increasing demand for their products and services in the pharmaceutical industry, particularly for sensitive and complex molecules in compliance with evolving regulatory standards.

The establishment of the Jurong facility comes at a crucial time when the advancement of biologics is transforming disease prevention, diagnosis, and treatment. This facility enables West to fulfil its customers' needs by offering high-quality containment products for injectable drugs in a single location within the Asia Pacific region, thereby reducing overall lead times for customers.

To cater to future demand, West has significantly expanded the Jurong facility, which now spans 18,000 m2. It is equipped with cutting-edge coating, pharmaceutical washing, sterilisation, and automated vision inspection capabilities for elastomers. These advancements minimise the risk of contamination and ensure compatibility with packaging components. Additionally, new moulding and compounding equipment with improved energy efficiency and automation capabilities have been installed.

With these enhancements, West's Jurong facility has the capacity to manufacture a comprehensive range of advanced containment products, including components with Westar™ Select quality level, Envision™ verification process, and FluroTec™ barrier film. This expansion addresses the healthcare industry's increasing focus on biologics, such as cell and gene therapeutics, while providing customers with enhanced on-the-ground technical support.

Eric Green, President, CEO, and Chair of the Board of Directors at West, stated: "As we celebrate West's 100th anniversary this year, we remain dedicated to strengthening our global networks to address the critical changes in healthcare and drug delivery. The investment in our Jurong facility plays a pivotal role in fulfilling our purpose of providing customers and patients worldwide with access to essential medicines."

West currently employs over 600 people across three locations in Singapore, including the JTC Summit Office, the Jurong plant, and the Gemini laboratory. The investment has already created more than 200 new jobs, and an additional 40 roles are expected to be added by the end of 2023.

More information online

Digital Edition

ILM 49.5 July

July 2024

Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...

View all digital editions


ADLM 2024

Jul 28 2024 San Diego, CA USA

InaLab 2024

Jul 30 2024 Jakarta, Indonesia


Jul 31 2024 Chengdu, China

ACS National Meeting - Fall 2024

Aug 18 2024 Denver, CO, USA


Aug 25 2024 Copenhagen, Denmark

View all events